This gene is often mutated in uveal melanoma (Van Raamsdonk, et al. 2010). A frequent mutation in GNA11 (Q209) can promote disease progression. Combined mTOR/PI3K and MEK inhibition is showing promises in preclinical studies (Khalili et al, 2012). In addition, a randomized, open-label, phase 2 clinical trial comparing selumetinib vs chemotherapy showed selumetinib resulted in a modestly improved progression-free survival and response rate; however, no improvement in overall survival was observed. Improvement in clinical outcomes was accompanied by a high rate of adverse events (Carvajal et al, 2014). Also, GNAQ and GNA11 mutations occur in 9.5% of mucosal melanoma and are associated with poor prognosis (Sheng et al, 2016).